Anteris Technologies Raises $200M in Public Offering, Secures Medtronic Investment
Event summary
- Anteris Technologies proposes a $200M public offering of common stock, with a potential $30M over-allotment option.
- Medtronic to invest up to $90M in a private placement, acquiring 16-20% of Anteris' post-offering shares.
- Proceeds to fund PARADIGM Trial for DurAVR® THV, expand manufacturing, and support R&D for v2vmedtech.
- Offering conducted under an effective Form S-3 registration statement filed January 8, 2026.
The big picture
Anteris' capital raise and Medtronic's strategic investment highlight growing competition in the transcatheter heart valve market. The $290M total funding potential positions Anteris to challenge established players like Edwards Lifesciences and Boston Scientific. This move comes as structural heart disease treatments increasingly shift toward minimally invasive solutions, with Medtronic's involvement suggesting validation of Anteris' biomimetic valve technology.
What we're watching
- Clinical Trial Momentum
- How the PARADIGM Trial's progress will validate DurAVR® THV's market potential.
- Strategic Alignment
- Whether Medtronic's investment signals long-term partnership potential beyond financing.
- Execution Risk
- The pace at which Anteris can scale manufacturing to meet anticipated demand.
Related topics